Skip to main content
. 2023 Jul 6;13:1204248. doi: 10.3389/fonc.2023.1204248
Author Radiation (within the previous 3 months) Antibiotics (within the previous 2 months) Age (years)
(<65 vs. ≥65)
PD-L1
(1%–49%)
PD-L1
(>50%)
Anti-PD(L)1 compound—nivolumab Anti-PD(L)1 compound—pembrolizumab Anti-PD(L)1 compound—atezolizumab
Umang Swami (11) 2.35 [1.36, 4.06]
p < 0.01
1.73 [1.00, 2.99]
p = 0.05
1.11 [0.95, 1.29]
p = 0.19
NA NA NA NA NA
A. Cortellini (12) NA 1.42 [0.91, 2.22]
p = 0.1207
NA 0.93 [0.61, 1.43]
p = 0.7731
0.59 [0.37, 0.94]
p = 0.0282
NA NA NA
Anne Schett (14) 1.60 [0.56, 4.51]
p = 0.38
3.71 [1.34, 10.4]
p = 0.01
0.98 [0.51, 1.90]
p = 0.96
7.08 [2.60, 19.3]
p < 0.01
3.29 [1.13, 9.58]
p = 0.03
4.29 [2.48, 7.39]
p < 0.01
2.12 [0.88, 5.08]
p = 0.09
1.09 [0.14, 18.47]
p = 0.93
Chirayu Mohindroo (15) NA 0.99 [0.76, 1.28]
p = 0.93
0.94 [0.73, 1.21]
p = 0.64
NA NA NA NA NA
L. Derosa-1 (17) NA 2.4 [1.1, 5.7]
p = 0.04
0.8 [0.4, 1.5] p = 0.43 NA NA NA NA NA
L. Derosa-2 (17) NA 2.9 [1.9, 4.4]
p < 0.01
1.3 [0.9, 1.9]
p = 0.23
NA NA NA NA NA
NADINA TINSLEY (18) NA 1.699
p = 0.002
1.012
p = 0.076
NA NA NA NA NA
Hyunho Kim (19) NA 2.476 [1.568, 3.911]
p < 0.001
NA 1.839 [0.67, 4.99]
p = 0.233
1.329 [0.52, 3.43]
p = 0.557
1.001, p = 0.363 1.31 [0.79, 2.173]
p = 0.295
0.801 [0.410, 1.564]
p = 0.516

F, female; M, male; HR, hazard ratio; NA, not available; ECOG PS, Eastern Cooperative Oncology Group performance status.